Publication | Closed Access

IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC

Pd-l1–selected NsclcOncologyMedicineImmune Checkpoint InhibitorPharmacotherapyAnti-cancer AgentCancer TreatmentLung CancerInterim Overall SurvivalPharmacologyPhase Iii StudyChemotherapy